TapewireFind a company

organization · Reporting owner

Catalyst4, Inc.

Disclosed activity across 1 company

Tapewire entity
22405
SEC CIK
0001900201

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
MapLight Therapeutics, Inc.MLPT · Entity 531610% ownerAugust 14, 2026August 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

MapLight Therapeutics, Inc.

Report date August 14, 2026 · Filed August 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Voting Common StockSEC Table I · non-derivativeIndirectSee footnote25,306,689 Reported balance After 2026-08-14 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2026-08-14 · Purchase · Acquired 4,400,000 · Balance 25,306,689

F1: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectSee footnote2,928,686 Reported balance After 2026-08-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-08-14 · Purchase · Acquired 2,928,686 · Balance 2,928,686

F2: The warrant is immediately exercisable, however, the warrant may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the reporting person immediately following such exercise would exceed 49.99%.

F3: The warrants will not expire until exercised in full.

F1: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

F2: The warrant is immediately exercisable, however, the warrant may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the reporting person immediately following such exercise would exceed 49.99%.

F3: The warrants will not expire until exercised in full.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 14, 2026 Filed Aug 18, 2026 22:55 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 PurchaseWarrants (right to buy) · Derivative 2,928,686 $11.38 Strike: $0.00 $33,328,153.81
Disclosure

SEC source: 0001900201-26-000005 · form4-08182026_100832.xml · derivative · entry 2

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,928,686

Underlying: Voting Common Stock · 2,928,686 shares

Expires not disclosed

F2 · derivative.exercise_date: The warrant is immediately exercisable, however, the warrant may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the reporting person immediately following such exercise would exceed 49.99%.

F3 · derivative.expiration_date: The warrants will not expire until exercised in full.

F1 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
August 14, 2026 Filed Aug 18, 2026 22:55 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 PurchaseVoting Common Stock 4,400,000 $11.38 $50,072,000.00
Disclosure

SEC source: 0001900201-26-000005 · form4-08182026_100832.xml · nonDerivative · entry 1

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 25,306,689

F1 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
July 30, 2026 Filed Jul 30, 2026 22:39 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 PurchaseVoting Common Stock 1,000,000 $13.00 $13,000,000.00
Disclosure

SEC source: 0001900201-26-000003 · form4-07302026_100713.xml · nonDerivative · entry 4

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 20,906,689

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
July 29, 2026 Filed Jul 30, 2026 22:39 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 PurchaseVoting Common Stock 3,000 $12.63 $37,890.00
Disclosure

SEC source: 0001900201-26-000003 · form4-07302026_100713.xml · nonDerivative · entry 3

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 19,906,689

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
July 28, 2026 Filed Jul 30, 2026 22:39 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 PurchaseVoting Common Stock 65,137 $11.69 $761,392.91
Disclosure

SEC source: 0001900201-26-000003 · form4-07302026_100713.xml · nonDerivative · entry 2

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 19,903,689

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.31 to $12.00, inclusive.

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
July 28, 2026 Filed Jul 30, 2026 22:39 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 PurchaseVoting Common Stock 141,088 $10.74 $1,515,510.86
Disclosure

SEC source: 0001900201-26-000003 · form4-07302026_100713.xml · nonDerivative · entry 1

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 19,838,552

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.295 to $11.28, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
October 28, 2025 Filed Oct 29, 2025 20:16 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 ConversionSeries D Preferred Stock · Derivative 6,678,910 Not disclosed Not disclosed
Disclosure

SEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 8

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Voting Common Stock · 6,678,910 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F8 · price: The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F8 · derivative.exercise_date: The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F8 · derivative.expiration_date: The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
October 28, 2025 Filed Oct 29, 2025 20:16 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 ConversionSeries C Preferred Stock · Derivative 5,444,807 Not disclosed Not disclosed
Disclosure

SEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 7

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Voting Common Stock · 5,444,807 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F7 · price: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F7 · derivative.exercise_date: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F7 · derivative.expiration_date: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
October 28, 2025 Filed Oct 29, 2025 20:16 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 ConversionSeries B-1 Preferred Stock · Derivative 275,148 Not disclosed Not disclosed
Disclosure

SEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 6

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Voting Common Stock · 275,148 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F6 · price: The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F6 · derivative.exercise_date: The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F6 · derivative.expiration_date: The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
October 28, 2025 Filed Oct 29, 2025 20:16 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 ConversionSeries B Preferred Stock · Derivative 1,263,768 Not disclosed Not disclosed
Disclosure

SEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 5

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Voting Common Stock · 1,263,768 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

F5 · price: The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

F5 · derivative.exercise_date: The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

F5 · derivative.expiration_date: The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
October 28, 2025 Filed Oct 29, 2025 20:16 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 ConversionSeries A-1 Preferred Stock · Derivative 444,846 Not disclosed Not disclosed
Disclosure

SEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 4

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Voting Common Stock · 444,846 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F4 · price: The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F4 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F4 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
October 28, 2025 Filed Oct 29, 2025 20:16 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 ConversionSeries A Preferred Stock · Derivative 148,809 Not disclosed Not disclosed
Disclosure

SEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 3

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Voting Common Stock · 148,809 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F3 · price: The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F3 · derivative.exercise_date: The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F3 · derivative.expiration_date: The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
October 28, 2025 Filed Oct 29, 2025 20:16 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 PurchaseVoting Common Stock 5,441,176 $17.00 $92,499,992.00
Disclosure

SEC source: 0001900201-25-000008 · form4-10292025_081047.xml · nonDerivative · entry 2

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 19,697,464

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document
October 28, 2025 Filed Oct 29, 2025 20:16 UTC MapLight Therapeutics, Inc. MLPT · Entity 5316 ConversionVoting Common Stock 14,256,288 Not disclosed Not disclosed
Disclosure

SEC source: 0001900201-25-000008 · form4-10292025_081047.xml · nonDerivative · entry 1

Catalyst4, Inc. · CIK 0001900201 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 14,256,288

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A, A-1, B, B-1, C and D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.